NDAORALTABLETPriority Review
Approved
May 2015
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
6
Data completeness
6/8 — Strong
Priority Review
VIBERZI (eluxadoline) by AbbVie is opioid mu-receptor agonists [moa]. Approved for irritable bowel syndrome with diarrhea, irritable bowel syndrome. First approved in 2015.
Drug data last refreshed Yesterday · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VIBERZI (eluxadoline) is an oral mu-opioid receptor agonist tablet approved by the FDA on May 27, 2015, and developed by AbbVie. The product is indicated for irritable bowel syndrome with diarrhea (IBS-D), working through opioid receptor mechanisms to modulate gut function. It represents a targeted therapeutic approach within the gastrointestinal disorder treatment landscape, offering an alternative mechanism to antidiarrheals and antimotility agents.
$0.1BPart D
6.9 years to LOEMechanism of Action
Opioid mu-Receptor Agonists
Pharmacologic Class:
mu-Opioid Receptor Agonist
Worked on VIBERZI at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.